Wyeth Pinning Near-Term Growth Hopes On Enbrel, Prevnar

The rheumatoid arthritis agent and pneumococcal conjugate vaccine are less sensitive to pricing pressure, giving them better growth prospects, the company says. Wyeth expects to file six "major" NDAs in next two years as it looks to new products to off-set pricing pressure over the long term.